

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of: Adam SIDDIQUI-JAIN

Serial No.: 10/531,545

Filing Date: (Int'l) October 20, 2003

For: PROCESSES FOR IDENTIFYING

QUADRUPLEX-TARGETED ANTIVIRAL MOLECULES Examiner: Not Yet Assigned

Group Art Unit: Not Yet Assigned

## INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97 & 1.98

MS PCT Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. §1.97 and § 1.98, Applicant submits for consideration in the above-identified application the documents listed on the attached Form PTO/SB/08a/b. Copies of foreign documents and non-patent literature are submitted herewith. The Examiner is requested to make these documents of record.

The document numbers 51, 60, and 93 listed on the attached Form PTO/SB/08a/b were cited in an International Search Report mailed on June 22, 2004, directed to a counterpart international or foreign application and have not been previously cited.

	his information disclosure statement is submitted:				
	With the application; accordingly, no fee or separate requirements are required.				
	Before the mailing of a first Office Action after the filing of a Request for Continued				
	Examination under § 1.114. However, if applicable, a certification under 37 C.F.R. § 1.9	<del>9</del> 7			
	(e)(1) has been provided.				
$\boxtimes$	Within three months of the application filing date or before mailing of a first Office Action	on			
	on the merits; accordingly, no fee or separate requirements are required. However, if				
	applicable, a certification under 37 C.F.R. § 1.97 (e)(1) has been provided.				
	After receipt of a first Office Action on the merits but before mailing of a final Office Action				
	or Notice of Allowance.				
	A fee is required. A check in the amount of is enclosed.				
	A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached	to			
	this submission in duplicate.				
	A Certification under 37 C.F.R. § 1.97(e) is provided above; accordingly; no fee	is			
	believed to be due.				
	After mailing of a final Office Action or Notice of Allowance, but before payment of the	;			
	issue fee.				
	A Certification under 37 C.F.R. § 1.97(e) is provided above and a check in the				
	amount of is enclosed.				

Applicant would appreciate the Examiner initialing and returning the Form PTO/SB/08a/b, indicating that the information has been considered and made of record herein.

form (PTO/SB/17 is attached to this submission in duplicate.)

A Certification under 37 C.F.R. § 1.97(e) is provided above and a Fee Transmittal

The information contained in this Information Disclosure Statement under 37 C.F.R. § 1.97 and § 1.98 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist;

(iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal form is separated from this document and the Patent and Trademark Office determines that an extension and/or other relief (such as payment of a fee under 37 C.F.R. § 1.17 (p)) is required, Applicant petitions for any required relief including extensions of time and authorizes the Commissioner to charge the cost of such petition and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing <u>532232000900</u>.

Dated: August <u>3</u>, 2005

Respectfully submitted,

Laurie L. Hill

Registration No.: 51,804 MORRISON & FOERSTER LLP

3811 Valley Centre Drive

Suite 500

San Diego, California 92130-2332

(858) 720-7955



Substitute for form 1449/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

BADENANDY.


(Use as many sheets as necessary)

Sheet	1	of	3

Complete if Known				
Application Number	10/531,545			
Filing Date	(Int'l) October 20, 2003			
First Named Inventor	Adam SIDDIQUI-JAIN			
Art Unit	Not Yet Assigned			
Examiner Name	Not Yet Assigned			
Attorney Docket Number	532232000900			

	U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Document Number  Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
	1.	US-4,469,863	09-04-1984	Ts'o et al.			
	2.	US-4,559,157	12-17-1985				
	3.	US-4,608,392	08-26-1986	Jacquet et al.			
	4.	US-4,820,508	04-11-1989				
	5.	US-4,938,949	07-03-1990	Borch et al.			
	6.	US-4,992,478	02-12-1991	Geria			
	7.	US-4,987,071	01-22-1991	Cech et al.			
	8.	US-5,093,246	03-03-1992	Cech et al.			
	9.	US-5,096,815	03-17-1992	Ladner et al.			
	10.	US-5,116,742	05-26-1992				
	11.	US-5,198,346	03-30-1993	Ladner et al.			
	12.	US-5,223,409		Ladner et al.			
	13.	US-5,403,484	04-04-1995				
	14.	US-5,536,821		Agrawal et al.			
	15.	US-5,541,306		Agrawal et al.			
	16.	US-5,571,698	11-05-1996				
	17.	US-5,614,622	03-25-1997	Radhakrishnan et al.			
	18.	US-5,637,683	06-10-1997	Usher et al.			
	19.	US-5,637,684	06-10-1997	Cook et al.	12		
	20.	US-5,654,398	08-05-1997	Frankel et al.			
	21.	US-5,700,922	12-23-1997	Cook et al.			
	22.	US-5,703,055	12-30-1997	Felgner et al.			
	23.	US-5,717,083	02-10-1998	Cook et al.			
	24.	US-5,719,262	02-17-1998	Buchardt et al.			
	25.	US-5,739,308	04-14-1998				
	26.	US-5,739,314	04-14-1998	Roy et al.			
	27.	US-5,759,768	06-02-1998				
	28.	US-5,766,905	06-16-1998	Studier et al.			
	29.	US-5,773,601	06-30-1998				
	30.	US-5,886,165	03-23-1999	Kandimalla et al.			
	31.	US-5,900,481	05-04-1999				
	32.	US-5,929,226		Padmapriya et al.			
	33.	US-5,955,599	09-21-1999	Radhakrishnan et al.			
	34.	US-5,962,674	10-05-1999				
	35.	US-5,977,296	11-02-1999				
	36.	US-6,022,688	02-08-2000	Jurinke et al.			
	37.	US-6,117,992	09-12-2000				
	38.	US-6,133,436	10-17-2000				
	39.	US-6,140,482	10-31-2000				
	40.	US-6,214,560		Yguerabide et al.			
	41.	US-6,261,776		Pirrung et al.			
	42.	US-6,316,781	11-13-2001				

Examiner	Date	
Signature	Considered	



43.	US-6,379,974	04-30-2002	Parce et al.	
44.	US-6,429,025	08-06-2002	Parce et al.	
45.	US-6,440,722	08-27-2002	Knapp et al.	
46.	US-2004/0005601-A1	01-08-2004	Siddiqui-Jain et al.	

	FOREIGN PATENT DOCUMENTS							
Examiner	Cite	Foreign Patent Document	Publication	Name of Patentee or	Pages, Columns, Lines,			
Initials*	No.1	Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	Date MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	T⁵		
	47.	WO-00/56746	09-28-2000	Kochkine et al.				
	48.	WO-00/75372	12-14-2000	Kim et al.				
	49.	WO-01/14398	03-01-2001	Garner				
	50.	WO-01/18234	03-15-2001	Austin et al.				
	51.	WO-02/072756	09-12-2002	Poeschla et al.				

\*EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at <a href="www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁵ Applicant is to place a check mark here if English language Translation is attached.

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	52.	ALTSCHUL et al., J. Mol. Biol. (1990) 215:403-410	
	53.	ALTSCHUL et al., Nucleic Acids Res. (1997) 25:3389-3402	
	54.	ANANTHA et al., Biochemistry (1998) 37:2709-2714	
-	55.	ANSELL et al., Current Opin. in Biotechnology (1996) 7:89-94	
	56.	ARTHANARI and BOLTON, Anti-Cancer Drug Design (1999) 14:317-326	
	57.	BARTEL and SZOSTAK, Science (1993) 261:1411-1418	
	58.	CARELL et al., Angew. Chem. Int. Ed. Engl. (1994) 33:2061-2064	_
	59.	CARELL et al., Angew. Chem. Int. Ed. Engl. (1994) 33:2059-2061	
	60.	CHARNEAU, J. of Virology (1992) 66:2814-2820	
	61.	CHO et al., Science (1993) 261:1303-1305	
	62.	Current Protocols in Molecular Biology, John Wiley & Sons, New York, (1989), pp. 6.3.1-6.3.6	
	63.	CWIRLA et al., PNAS USA (1990) 87:6378-6382	
	64.	DATTA et al., JACS (2001) 123:9612-9619	
	65.	DEVLIN, Science (1990) 249:404-406	
	66	DE WITT et al., PNAS USA (1993) 90:6909-6913	
	67.	ELBASHIR et al., Methods (2002) 26:199-213	
	68.	ERB et al., PNAS USA (1994) 91:11422	
	69.	FELICI, J. Mol. Biol. (1991) 222:301-310	
	70.	FODOR, Nature (1993) 364:555-556	
	71.	GALLOP et al., J. Med. Chem. (1994) 37:1233-1251	
	72.	HAN et al., Nucl. Acids. Res. (1999) 27:537-542	

Examiner	Date
Signature	Considered

## ALTERNATIVE TO PTO/SB/08a/b (06-03)

Substitute for form 1449/PTO				Complete if Known		
				Application Number	10/531,545	
11	NFORMATIC	ON DISC	CLOSURE	Filing Date	(Int'l) October 20, 2003	
S	STATEMENT BY APPLICANT			First Named Inventor	Adam SIDDIQUI-JAIN	
				Art Unit	Not Yet Assigned	
	(Use as many sheets as necessary)			Examiner Name	Not Yet Assigned	
Sheet	3	of	3	Attorney Docket Number	532232000900	

73.	HASELHOFF & GERLACH, Nature (1988) 334:585-591	
74.	HE et al., Science (1998) 281:1509-1512	
75.	HURLEY, Nature Rev. Cancer (2002) 2:188-200	
76.	International Search Report for PCT/US03/33366, mailed on June 22, 2004, 1 page	
77.	JIN and PIKE, Mol. Endocrinol. (1996) 10:196-205	
78.	KIM et al., J. Virol. (1998) 72:811-816	
79.	KRIZ et al., Analytical Chemistry (1995) 67:2142-2144	
80.	LAM, Nature (1991) 354:82-84	
81.	LYONNAIS et al., Nucleic Acids Research (2002) 30:5276-5283	
82.	MEYERS & MILLER, CABIOS (1989) 4:11-17	
83.	POSTEL et al., Mol. Cell. Biol. (1989) 9:5123-5133	
84.	POSTEL, J. Biol. Chem. (1999) 274:22821-22829	
85.	QU and CHAIRES, Methods Enzymol. (2000) 321:353-369	
86.	REN et al., Biochemistry (1999) 38:16067-16075	
87.	SCOTT and SMITH, Science (1990) 249:386-390	
. 88.	SHEA, Trends in Polymer Science (1994) 2:166-173	
89.	SIMONSSON and SJOBACK, J. Biol. Chem. (1999) 274:17379-17383	
90.	SONEOKA et al., Nucleic Acids Res. (1995) 23:628-633	
91.	VLATAKIS et al., Nature (1993) 361:645-647	
92.	WEITZMANN et al., J. Biol. Chem. (1996) 271:20958-20964	
93.	WHITWAM, J. of Virology (2001) 75:9407-9414	
94.	ZUCKERMANN et al., J. Med. Chem. (1994) 37:2678-2685	
	74. 75. 76. 77. 78. 79. 80. 81. 82. 83. 84. 85. 86. 87. 88. 89. 90. 91. 92. 93.	74. HE et al., Science (1998) 281:1509-1512  75. HURLEY, Nature Rev. Cancer (2002) 2:188-200  76. International Search Report for PCT/US03/33366, mailed on June 22, 2004, 1 page  77. JIN and PIKE, Mol. Endocrinol. (1996) 10:196-205  78. KIM et al., J. Virol. (1998) 72:811-816  79. KRIZ et al., Analytical Chemistry (1995) 67:2142-2144  80. LAM, Nature (1991) 354:82-84  81. LYONNAIS et al., Nucleic Acids Research (2002) 30:5276-5283  82. MEYERS & MILLER, CABIOS (1989) 4:11-17  83. POSTEL et al., Mol. Cell. Biol. (1989) 9:5123-5133  84. POSTEL, J. Biol. Chem. (1999) 274:22821-22829  85. QU and CHAIRES, Methods Enzymol. (2000) 321:353-369  86. REN et al., Biochemistry (1999) 38:16067-16075  87. SCOTT and SMITH, Science (1990) 249:386-390  88. SHEA, Trends in Polymer Science (1994) 2:166-173  89. SIMONSSON and SJOBACK, J. Biol. Chem. (1999) 274:17379-17383  90. SONEOKA et al., Nucleic Acids Res. (1995) 23:628-633  91. VLATAKIS et al., Nature (1993) 361:645-647  92. WEITZMANN et al., J. Biol. Chem. (1996) 271:20958-20964  93. WHITWAM, J. of Virology (2001) 75:9407-9414

<sup>\*</sup>EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner	Date	
Signature	Considered	

<sup>&</sup>lt;sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.